China's International Medical Tourism in 2026 vs Thailand and India
Asia dominates global medical travel, and its three big destinations follow very different playbooks. According to industry reports and national tourism authorities, Thailand received roughly 580,000 international patients in 2025, India recorded about 507,000 medical-visa entries, and China served around 413,000 international patients โ the smallest of the three, but growing fastest at about 63% year on year. This article compares the three systems as they stand in 2026 and explains what China's pilot zones change for patients.
A fast-growing global market, led by Asia
Industry reports describe global medical tourism as a market in sustained double-digit growth through the 2020s and into the 2030s, with Asian destinations โ Thailand, India, Singapore, South Korea, Malaysia โ taking a leading share. The interesting part is not the growth itself but how differently the three largest Asian systems are built.
Thailand made medical travel a national strategy in 2004 and built a hospitality-grade service system around it. India positioned itself as a high-volume destination for complex specialist surgery. China entered last: its pilot programme for international patient services at selected hospitals began in 2023, yet its growth rate in 2025 was the highest of the three, according to figures cited in industry analyses.
Thailand: two decades of system-building
Thailand is widely treated as the reference model in industry literature. Per Thai tourism authorities, the country expected around 580,000 international medical travellers in 2025, and industry counts put its internationally accredited (JCI) hospitals at more than 60, with several hundred further facilities equipped to receive foreign patients.
Its distinguishing features are policy and service integration rather than any single technology. The Destination Thailand Visa introduced in 2024 allows stays of up to 180 days per entry with five-year validity, long enough for surgery plus resort-based recovery. Airport pickup, interpreting, escorted appointments, rehabilitation and post-operative holidays are packaged by specialised agencies into a single product โ a service chain built over twenty years.
India: scale and specialist surgery
India follows a different formula, described in industry reports as 'medical value travel': very large volumes of complex specialist procedures โ cardiac surgery, transplants, orthopaedics, oncology โ delivered by large private hospital chains that have standardised these workflows to a high degree. Official medical-visa statistics recorded about 507,000 entries in 2025, while broader industry estimates that include other visa categories run substantially higher, drawing patients from dozens of countries.
India also pairs modern medicine with its traditional Ayurveda sector as a wellness product. Industry analyses note the trade-offs: quality and experience vary considerably between facilities, and post-treatment recovery infrastructure is generally considered less developed than Thailand's.
China: the fastest-growing newcomer
China's international patient volume โ around 413,000 in 2025, according to figures cited in industry reports โ is the smallest of the three, from a hospital system that is by far the largest. The growth story is recent: a first batch of 13 hospitals was designated for international patient services in 2023, and the 2025 volume grew about 63% year on year.
Industry analyses consistently name the same structural gaps: China has no dedicated medical visa (patients enter on tourist or business visas), only around two dozen JCI-accredited hospitals nationwide, limited direct-billing arrangements with international insurers, and a fragmented service chain compared with Thailand's packaged model. The same analyses also note China's strengths: deep clinical capacity in complex specialties, strong cost competitiveness, and traditional Chinese medicine as a differentiator no competitor can replicate.
What pilot zones change: the Boao Lecheng example
China's answer to its structural gaps so far is concentrated in pilot zones, and Boao Lecheng in Hainan is the most developed example. The zone operates under a special policy that lets licensed hospitals use drugs and medical devices already approved in other major jurisdictions before nationwide Chinese approval โ meaning some internationally available therapies reach Lecheng years earlier than the rest of the country.
Two access features matter for international patients. First, Hainan's visa-free entry policy covers citizens of 86 countries for stays of up to 30 days with an ordinary passport, and medical purposes are accepted โ which partially substitutes for the missing medical visa for eligible nationalities. Second, the zone concentrates internationally oriented clinics, licensed early-access therapies and service infrastructure in one place. Per the zone administration's published figures, Lecheng received close to 500,000 medical-tourism visits in the first four months of 2026, of which over 4,000 were international โ small in absolute terms, but the mechanism is in place and growing.
What to watch in 2026
Industry commentary converges on a short watch-list for China: whether a dedicated medical visa with treatment-length stays is introduced; whether direct billing with major international insurers is piloted (Hainan and Shanghai are the frequently named candidates); whether the number of internationally accredited hospitals expands; and whether integrated service operators emerge to package the journey the way Thai agencies do.
For patients, the practical takeaway in 2026 is this: Thailand offers the smoothest packaged experience, India offers scale in specialist surgery, and China offers rapidly improving access to a very deep clinical system โ with pilot zones like Lecheng already removing the visa barrier for many nationalities and offering therapies not yet available nationwide. Which destination fits depends on the condition, the therapy needed and the patient's nationality, not on any single ranking.
| Indicator | Thailand | India | China |
|---|---|---|---|
| International patients (2025) | ~580,000 | ~507,000 medical-visa entries; higher by broader estimates | ~413,000 (+63% year on year) |
| JCI-accredited hospitals | 60+ | Limited; domestic NABH accreditation dominates | ~23 |
| Dedicated medical visa | Yes โ DTV, up to 180 days per stay, 5-year validity | Yes โ medical visa | Not yet; tourist/business visas; Hainan: visa-free entry for 86 countries up to 30 days |
| National strategy since | 2004 | Long-standing, progressively extended | 2023 pilot programme (13 hospitals) |
Frequently asked questions
Is treatment in China cheaper than in Thailand or India?
Does China have a medical visa?
What is the Boao Lecheng pilot zone?
How reliable are the figures in this article?
This article was produced with AI assistance and reviewed against Uwell Cloud editorial and compliance standards.